{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:25:53Z","timestamp":1792571153014,"version":"4.5.0"},"reference-count":101,"publisher":"American Diabetes Association","issue":"1","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,1]]},"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic steatohepatitis (NASH), can promote the development of cirrhosis, hepatocellular carcinoma, cardiovascular disease, and type 2 diabetes. Similarly, type 2 diabetes confers the greatest risk for the development of NASH, especially when associated with obesity. Although lifestyle changes are critical to success, early implementation of pharmacological treatments for obesity and type 2 diabetes are essential to treat NASH and avoid disease progression. This article reviews current guidance regarding the use of pharmacological agents such as pioglitazone, glucagon-like peptide 1 receptor agonists, and sodium\u2013glucose cotransporter 2 inhibitors in the setting of NAFLD and NASH. It also reviews the latest information on new drugs currently being investigated for the treatment of NASH.<\/jats:p>","DOI":"10.2337\/dsi23-0012","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T20:25:53Z","timestamp":1708028753000},"page":"48-58","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":72,"title":["Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies"],"prefix":"10.2337","volume":"37","author":[{"given":"Idoia","family":"Genua","sequence":"first","affiliation":[{"name":"1IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8629-418X","authenticated-orcid":false,"given":"Kenneth","family":"Cusi","sequence":"additional","affiliation":[{"name":"2Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2024021520254468000_B1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/dsi23-0009","article-title":"Practical lifestyle management of nonalcoholic fatty liver disease for busy clinicians","volume":"37","author":"Zelber-Sagi","year":"2024","journal-title":"Diabetes Spectr"},{"key":"2024021520254468000_B2","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"2024021520254468000_B3","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.2337\/dc23-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B4","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"2024021520254468000_B5","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"key":"2024021520254468000_B6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.clnesp.2022.03.020","article-title":"Understanding weight regain after a nutritional weight loss intervention: systematic review and meta-analysis","volume":"49","author":"Machado","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"2024021520254468000_B7","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"2024021520254468000_B8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep"},{"key":"2024021520254468000_B9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024021520254468000_B10","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B11","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/oby.23263","article-title":"Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease","volume":"29","author":"Barb","year":"2021","journal-title":"Obesity (Silver Spring)"},{"key":"2024021520254468000_B12","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"key":"2024021520254468000_B14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2337\/dc20-1997","article-title":"Advanced liver fibrosis is common in patients with type 2 diabetes followed in the outpatient setting: the need for systematic screening","volume":"44","author":"Lomonaco","year":"2021","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B15","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1530\/EJE-20-1240","article-title":"Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study","volume":"184","author":"Juli\u00e1n","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2024021520254468000_B16","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/jcm9041032","article-title":"Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience","volume":"9","author":"Sporea","year":"2020","journal-title":"J Clin Med"},{"key":"2024021520254468000_B17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/hep.27981","article-title":"Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam Study","volume":"63","author":"Koehler","year":"2016","journal-title":"Hepatology"},{"key":"2024021520254468000_B18","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1002\/hep.32560","article-title":"NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status","volume":"76","author":"Kim","year":"2022","journal-title":"Hepatology"},{"key":"2024021520254468000_B19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/dci19-0064","article-title":"Time to include nonalcoholic steatohepatitis in the management of patients with type 2 diabetes","volume":"43","author":"Cusi","year":"2020","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B20","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dci21-0020","article-title":"Preparing for the NASH epidemic: a call to action","volume":"44","author":"Kanwal","year":"2021","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Curr Diab Rep"},{"key":"2024021520254468000_B22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","article-title":"Advancing the global public health agenda for NAFLD: a consensus statement","volume":"19","author":"Lazarus","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024021520254468000_B23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1210\/clinem\/dgac624","article-title":"Approach to the patient with nonalcoholic fatty liver disease","volume":"108","author":"Belfort-DeAguiar","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021520254468000_B24","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/1479164118825376","article-title":"Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes","volume":"16","author":"DeFronzo","year":"2019","journal-title":"Diab Vasc Dis Res"},{"key":"2024021520254468000_B26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s11892-019-1270-y","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"19","author":"Lebovitz","year":"2019","journal-title":"Curr Diab Rep"},{"key":"2024021520254468000_B27","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/liv.15005","article-title":"PPAR-\u03b3-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH","volume":"41","author":"Gastaldelli","year":"2021","journal-title":"Liver Int"},{"key":"2024021520254468000_B28","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2337\/diacare.23.11.1605","article-title":"Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study: the Pioglitazone 001 Study Group","volume":"23","author":"Aronoff","year":"2000","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B29","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B30","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"2024021520254468000_B31","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann Intern Med"},{"key":"2024021520254468000_B32","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B33","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s12072-021-10242-2","article-title":"First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients","volume":"15","author":"Huang","year":"2021","journal-title":"Hepatol Int"},{"key":"2024021520254468000_B34","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: a randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B35","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B36","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B37","doi-asserted-by":"crossref","first-page":"dgz252","DOI":"10.1210\/clinem\/dgz252","article-title":"Pioglitazone for the primary and secondary prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis","volume":"105","author":"Zhou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021520254468000_B38","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"2024021520254468000_B39","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12933-021-01294-7","article-title":"Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug","volume":"20","author":"Nesti","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2024021520254468000_B40","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1001\/jama.299.13.1561","article-title":"Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial","volume":"299","author":"Nissen","year":"2008","journal-title":"JAMA"},{"key":"2024021520254468000_B41","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/dom.14885","article-title":"Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes","volume":"25","author":"Moody","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2024021520254468000_B42","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.2337\/dc23-S003","article-title":"3. Prevention or delay of type 2 diabetes and associated comorbidities: Standards of Care in Diabetes\u20142023","volume":"46","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B43","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4158\/EP.9.5.406","article-title":"Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications","volume":"9","author":"Mudaliar","year":"2003","journal-title":"Endocr Pract"},{"key":"2024021520254468000_B44","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2337\/diacare.27.1.256","article-title":"Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association","volume":"27","author":"Nesto","year":"2004","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B45","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1592\/phco.26.10.1388","article-title":"Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus","volume":"26","author":"Jain","year":"2006","journal-title":"Pharmacotherapy"},{"key":"2024021520254468000_B46","doi-asserted-by":"crossref","first-page":"502","DOI":"10.2174\/1871530318666180423121833","article-title":"Pioglitazone therapy and fractures: systematic review and meta-analysis","volume":"18","author":"Pavlova","year":"2018","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"2024021520254468000_B47","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021520254468000_B48","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/1753-0407.12833","article-title":"Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: a 36-month clinical trial","volume":"11","author":"Portillo-Sanchez","year":"2019","journal-title":"J Diabetes"},{"key":"2024021520254468000_B49","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"2024021520254468000_B50","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S2213-8587(17)30317-0","article-title":"Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial","volume":"5","author":"Vaccaro","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024021520254468000_B51","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/pds.4154","article-title":"Pioglitazone and bladder cancer: FDA\u2019s assessment","volume":"26","author":"Hampp","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024021520254468000_B52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern Med"},{"key":"2024021520254468000_B53","doi-asserted-by":"crossref","first-page":"615409","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024021520254468000_B54","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT)","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"2024021520254468000_B55","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"2024021520254468000_B56","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2023","journal-title":"Endocr Rev"},{"key":"2024021520254468000_B58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/clinem\/dgab578","article-title":"The emerging role of glucagon-like peptide-1 receptor agonists for the management of NAFLD","volume":"107","author":"Patel Chavez","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021520254468000_B59","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/dom.14943","article-title":"Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: a post hoc analysis of the SURPASS-1 to -5 studies","volume":"25","author":"Lingvay","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2024021520254468000_B60","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2024021520254468000_B61","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1210\/jc.2015-3906","article-title":"Mechanisms of action of liraglutide in patients with type 2 diabetes treated with high-dose insulin","volume":"101","author":"Vanderheiden","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021520254468000_B62","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/dom.13053","article-title":"Effect of liraglutide on ectopic fat in polycystic ovary syndrome: a randomized clinical trial","volume":"20","author":"Fr\u00f8ssing","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2024021520254468000_B63","doi-asserted-by":"crossref","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","article-title":"Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial","volume":"170","author":"Guo","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"2024021520254468000_B64","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2024021520254468000_B65","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-019-05021-6","article-title":"Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation","volume":"63","author":"Bizino","year":"2020","journal-title":"Diabetologia"},{"key":"2024021520254468000_B66","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"2024021520254468000_B67","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B68","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1097\/HEP.0000000000000263","article-title":"Diabetes and cirrhosis: current concepts on diagnosis and management","volume":"77","author":"Castera","year":"2023","journal-title":"Hepatology"},{"key":"2024021520254468000_B69","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024021520254468000_B70","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2024021520254468000_B71","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-022-01512-w","article-title":"The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management","volume":"21","author":"Xu","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2024021520254468000_B72","doi-asserted-by":"crossref","first-page":"155396","DOI":"10.1016\/j.metabol.2022.155396","article-title":"Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrte metabolism in prediabetic insulin resistant individuals: a randomized, double-blind crossover trial","volume":"140","author":"Veelen","year":"2023","journal-title":"Metabolism"},{"key":"2024021520254468000_B73","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.3390\/ijms23063107","article-title":"SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection","volume":"23","author":"Androutsakos","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024021520254468000_B74","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: a randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients","volume":"42","author":"Latva-Rasku","year":"2019","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B76","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2024021520254468000_B77","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/ph15121516","article-title":"The impact of an SGLT2 inhibitor versus ursodeoxycholic acid on liver steatosis in diabetic patients","volume":"15","author":"Elhini","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024021520254468000_B78","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2024021520254468000_B79","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2024021520254468000_B80","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv Ther"},{"key":"2024021520254468000_B81","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther"},{"key":"2024021520254468000_B82","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"2024021520254468000_B83","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.2337\/dc21-2049","article-title":"Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial","volume":"45","author":"Takeshita","year":"2022","journal-title":"Diabetes Care"},{"key":"2024021520254468000_B84","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"key":"2024021520254468000_B85","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B86","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B87","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s13679-022-00474-0","article-title":"Anti-obesity medications for the management of nonalcoholic fatty liver disease","volume":"11","author":"Polyzos","year":"2022","journal-title":"Curr Obes Rep"},{"key":"2024021520254468000_B88","first-page":"90","article-title":"Efficacy of orlistat in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"9","author":"Wang","year":"2018","journal-title":"Biomed Rep"},{"key":"2024021520254468000_B89","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/hep.22575","article-title":"Orlistat for overweight subjects with nonalcoholic steatohepatitis: a randomized, prospective trial","volume":"49","author":"Harrison","year":"2009","journal-title":"Hepatology"},{"key":"2024021520254468000_B90","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/dom.14284","article-title":"Extended-release naltrexone\/bupropion and liver health: pooled, post hoc analysis from four randomized controlled trials","volume":"23","author":"Bajaj","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2024021520254468000_B91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/jgh.15221","article-title":"Systematic review with meta-analysis: the effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease","volume":"36","author":"Vadarlis","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2024021520254468000_B92","doi-asserted-by":"crossref","first-page":"777131","DOI":"10.3389\/fcvm.2021.777131","article-title":"Statins in non-alcoholic steatohepatitis","volume":"8","author":"Torres-Pe\u00f1a","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2024021520254468000_B93","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1210\/jc.2017-00867","article-title":"Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post hoc analysis of a randomized trial","volume":"102","author":"Bril","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021520254468000_B94","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"2024021520254468000_B95","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B96","first-page":"31","article-title":"Lanifibranor reverses insulin resistance and improves glucose and lipid metabolism in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease (MASLD) [Abstract 5035C]","author":"Barb","year":"2023"},{"key":"2024021520254468000_B97","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"2024021520254468000_B98","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"key":"2024021520254468000_B99","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/dom.14319","article-title":"Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: EXENDA, a 24-week, prospective, randomized, placebo-controlled pilot trial","volume":"23","author":"Harreiter","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2024021520254468000_B100","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2024021520254468000_B101","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"}],"container-title":["Diabetes Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/spectrum\/article-pdf\/37\/1\/48\/746878\/diaspectdsi230012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/spectrum\/article-pdf\/37\/1\/48\/746878\/diaspectdsi230012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T20:26:37Z","timestamp":1708028797000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/spectrum\/article\/37\/1\/48\/154182\/Pharmacological-Approaches-to-Nonalcoholic-Fatty"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,2,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dsi23-0012","relation":{},"ISSN":["1040-9165","1944-7353"],"issn-type":[{"value":"1040-9165","type":"print"},{"value":"1944-7353","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}